
This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.

Join experts Drs. Amy Paller and Peter Lio at an educational symposium as they investigate atopic dermatitis as a risk factor for the development of food allergies. The speakers will also discuss the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.

An interactive tool used to explore the global burden of atopic dermatitis in children and adolescents.

Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.